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As the armamentarium of antipsychotic medications continues to grow, so does 
data supporting expansion of their use for conditions beyond schizophrenia. For 
this reason, providers other than psychiatrists may see increasing numbers of 
patients on these medications and need to have an understanding of how to 
manage such patients.  It is, therefore, important to take a moment to remind 
ourselves that while efficacious, these medications do not come without risk. The 
potential for extrapyramidal symptoms causes concern with first generation 
antipsychotics and has played a role in the shift toward increased use of second 
generation antipsychotics (SGAs), such as olanzapine, quetiapine, risperidone, 
ziprasidone, or paliperidone. This is due to the fact that SGAs are less likely to 
cause such movement disorders. The switch comes with a tradeoff, however. SGAs 
have been shown to increase patients’ risk of developing metabolic syndrome.1 
 
According to the Adult Treatment Panel III (ATP III) guidelines, diagnosis of 
metabolic syndrome involves evaluation of five main domains: abdominal 
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circumference, triglyceride (TG) levels, high-density lipoprotein (HDL) levels, blood pressure, and 
fasting glucose levels. Abnormalities in three or more of these areas are indicative of metabolic 
syndrome. Such abnormalities include: 
 Waist circumference over 102cm for men or 88cm for women 
 TGs greater than or equal to 150mg/dL 
 HDL less than 40mg/dL for men and less than 50mg/dL for women 
 Blood pressure greater than or equal to 130/85mmHg2 
 Fasting glucose greater than or equal to 100mg/dL2,3 
 
Changes in these parameters and the development of metabolic syndrome can have a large impact 
on a patient’s health and lead to long term complications. If not addressed, patients may develop 
diabetes or cardiovascular disease.1 Obesity alone is associated with multiple comorbidities such as 
hypertension, sleep apnea, and stroke, which may lead to increased mortality and morbidity.4 These 
multitudes of potential complications may in turn lead to increased medication use or 
hospitalizations. It is, therefore, important to proactively seek opportunities to prevent them by 
identifying and monitoring patients at high risk for metabolic syndrome.  
 
Certain populations have an increased risk of developing metabolic disorders. Among these are 
patients with mental health conditions such as schizophrenia or bipolar disorder.5 When these 
patients are treated with SGAs, as is often the case, the potential for metabolic problems, including 
hypertriglyceridemia and insulin resistance, is amplified.1,6 The mechanism by which SGAs pose this 
risk is not fully understood, but is likely multifactorial. Patients taking these medications may notice 
an increase in appetite or a craving for carbohydrate rich food, eventually leading to obesity and 
related complications. SGAs may also have a direct impact on patients’ lipid profiles, increasing TGs 
and lowering HDL levels. Among other theories is the thought that activity at serotonin 2C 
(5HT2c), histamine 1 (H1), and muscarinic 3 (M3) receptors leads to increased appetite, weight gain, 
and metabolic syndrome.6  
 
Looking at the receptor profiles of many of the higher risk antipsychotics, this theory makes sense. 
The SGAs clozapine, olanzapine, and quetiapine all antagonize these three receptors, and all are 
highly associated with weight gain.7 The receptor theory also helps to explain the risks associated 
with low doses of quetiapine, such as those used off-label for sleep. At low doses, quetiapine is 
more selective for H1 receptors and therefore poses as much of a metabolic risk as a dose used for 
treating psychosis.6-8 For this reason, careful consideration should be made before starting someone 
on quetiapine simply to help with sleep.  
 
Other SGAs, especially newer agents, are marketed as being less likely to cause weight gain or 
metabolic syndrome. Aripiprazole, ziprasidone, lurasidone, asenapine, and iloperidone are among 
such agents, and may be considered if metabolic complications are a concern or if a patient is unable 
to tolerate other SGAs. Risperidone and its metabolite, paliperidone, have moderate potential to 
cause weight gain, but evidence linking them to diabetes and hypertriglyceridemia is not as 
conclusive as with clozapine and olanzapine.1,6,7,9  
 
While avoidance of the higher risk medications would help ameliorate the risk of metabolic 
complications, this is not always practical. Additionally, all SGAs increase the risk of metabolic 
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complications to varying degrees.1 Therefore it is important to diligently monitor for adverse 
metabolic effects among patients on these medications. Doing so will help with early detection and 
management of the problem.  
 
To properly monitor these patients, guidelines recommend taking a thorough medical and family 
history and obtaining a baseline body mass index (BMI), waist circumference, blood pressure, fasting 
glucose, and fasting lipid profile. Thereafter, the following monitoring schedule is recommended:  
 Weeks 4 and 8: BMI 
 Week 12: BMI, blood pressure, fasting glucose, and fasting lipids 
 Quarterly after week 12: BMI 
 Annually: medical and family history update, waist circumference, blood pressure, and 
fasting glucose 
 Every 5 years: fasting lipids1 
 
Patients who have abnormal results within these time frames should be monitored more closely 
until they stabilize. Additionally, monitoring for patients switched to a new SGA should restart 
according to the recommended schedule.1  
  
If metabolic profiles are found to be out of range or consistently worsening for a patient, lifestyle 
modifications should be implemented. It is also likely they could benefit from being switched to a 
different SGA. An agent with lower metabolic risks would be preferred in such cases, although 
other medication and patient specific characteristics should not be overlooked. For patients in 
whom switching is not an appropriate option, medical management of their lipids, weight, and blood 
pressure may be needed to prevent long term complications.1 
  
Management of these problems, however, can become complex as multiple providers may be 
involved in a patient’s care. This issue of a psychiatric medication causing problems typically 
managed in a primary care setting highlights the need for collaboration among multiple disciplines.5 
In order to ensure that patients on these medications adhere to a proper monitoring regimen, all 
providers should perform recommended monitoring. Results and treatment plans should then be 
shared to allow for better interdisciplinary collaboration and to prevent repetitive testing.  
 
Close follow-up and monitoring of patients on SGAs is paramount. Apart from clinical efficacy, 
providers should also continually evaluate the metabolic effects of these drugs.1,6  While the risks 
associated with these medications cannot always be avoided, close follow-up can decrease the rates 
of untoward effects and play a role in the successful long-term use of these medications.   
 
 
REFERENCES 
1.
 American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, 
North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs 
and obesity and diabetes. Diabetes Care.2004; 27(2): 569-601. 
2. National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) expert panel on 
detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). NIH Publication 
No. 02-5215. 2002 Sept. 
 
Page 4 
3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2013; 36: S67-S74.   
4. National Institutes of Health. Clinical guidelines on the identification, evaluation, and treatment of overweight and 
obesity in adults. NIH Publication No. 98-4083. 1998 Sept.  
5. Balf G, Stewart TD, Whitehead R, Baker R. Metabolic adverse events in patients treated with antipsychotics: A 
primary care perspective. Prim Care Companion J Clin Psychiatry. 2008; 10(1): 15-24.  
6. Stahl SM, Mignon L, Meyer JM. Which comes first: atypical antipsychotic treatment or cardiometabolic risk? Acta 
Psychiatr Scand. 2009; 119: 171-179.  
7. Stahl SM. Antipsychotic agents. In: Stahl’s essential psychopharmacology: neuroscientific basis and practical 
applications. 3rd ed. New York: Cambridge University Press; 2008.  
8. Gugger JJ, Cassagnol M. Low-dose quetiapine is not a benign sedative-hypnotic agent. Am J Addict. 2008; 17: 454-
455.  
9. Lexi DrugsTM [Internet]. Hudson (OH); Lexi-Comp, Inc. [cited 2013 May 28]. Available from: http://online.lexi.com/
lco/action/home. 
 
 
Diagnostic Dilemma 
Sudharshan Balla, MD 
Fellow, Division of Cardiovascular Diseases, University of Missouri Health Care 
 
 
Questions: 
 
1)  A 37 year old female is admitted with increasing dyspnea and orthopnea of 1 week duration. She 
had received chemotherapy and radiation for breast cancer 1 year ago. On exam she has elevated 
JVP and diminished breath sounds at bases. Bilateral lower extremities have 2+ pitting edema.  
Which of the following conditions could be the potential culprits leading to this presentation? 
 
A)  Cardiac Tamponade 
B)   Dilated Cardiomyopathy 
C)  Constrictive Pericarditis 
D)  Restrictive Cardiomyopathy 
E)  All the above 
  
 
2)  A 68 year old male with history of hypertension was admitted with a blood pressure of 220/120 
mm/Hg. He has been on treatment for hypertension and has a known history of paroxysmal atrial 
fibrillation and coronary artery disease. His home medications include amiodarone, amlodipine, 
aspirin, losartan and hydrochlorothiazide. He was diagnosed with hypertensive urgency and 
treated with labetalol. Which of the following is the least likely cause of hypertensive urgency in 
this patient? 
 
A)  Drug induced hypertension 
B)  Primary Hyperaldosteronism 
C)  Renal artery atherosclerosis 
D)  Fibromuscular dysplasia 
